Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 8/20 | 0.60 |
| ▸ | CASP3 | P42574 | 13/20 | 0.55 |
| ▸ | CASP8 | Q14790 | 12/20 | 0.55 |
| ▸ | CASP6 | P55212 | 11/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005347 | 1.00 | CASP1 (0.60) | CASP1CASP3CASP8CASP6CASP7 | |
| SCHEMBL473146 | 1.00 | CASP1 (0.60) | CASP1CASP3CASP8CASP6CASP7 | |
| SCHEMBL473149 | 1.00 | CASP1 (0.60) | CASP1CASP3CASP8CASP6CASP7 | |
| SCHEMBL12567733 | 0.95 | CASP1 (0.57) | CASP1CASP3CASP8CASP6CASP7 | |
| SCHEMBL12567782 | 0.95 | CASP1 (0.57) | CASP1CASP3CASP8CASP6CASP7 | |
| SCHEMBL12567783 | 0.95 | CASP1 (0.57) | CASP1CASP3CASP8CASP6CASP7 | |
| SCHEMBL473187 | 0.93 | CASP1 (0.61) | CASP1CASP3CASP8CASP6CASP7 | |
| SCHEMBL6005359 | 0.93 | CASP1 (0.61) | CASP1CASP3CASP8CASP6CASP7 | |
| SCHEMBL473098 | 0.93 | CASP1 (0.61) | CASP1CASP3CASP8CASP6CASP7 | |
| SCHEMBL2003509 | 0.93 | CASP1 (0.61) | CASP1CASP3CASP8CASP6CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| US-20240268372-A1 | Methods and Compositions for Extending Organ and Tissue Preservation | MASSACHUSETTS GEN HOSPITAL (US) | 2024-08-15 | — | — | US | claimed |
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | ILAB (KR) | 2023-12-26 | — | — | US | claimed |
| CN-116745289-A | Agonists of free fatty acid receptor 1 and their use in diseases associated with said receptor | 奥洛治疗有限公司 | 2023-09-12 | — | — | CN | claimed |
| EP-4232448-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2023-08-30 | — | — | EP | claimed |
| US-20230099574-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2023-03-30 | — | — | US | claimed |
| WO-2022241417-A1 | METHODS AND COMPOSITIONS FOR EXTENDING ORGAN AND TISSUE PRESERVATION | THE GENERAL HOSPITAL CORPORATION (US) | 2022-11-17 | — | — | WO | claimed |
| WO-2022123062-A1 | BLOCKING CASPASE AND/OR FASL FOR PREVENTING FATAL OUTCOME IN COVID-19 PATIENTS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-06-16 | — | — | WO | claimed |
| WO-2022083853-A1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | GBIOTECH S.À.R.L. (CH) | 2022-04-28 | — | — | WO | claimed |
| EP-4747359-A2 | HUMAN VASCULARIZED INTEGRATED ORGAN SYSTEM AND APPLICATIONS THEREOF | 3D Systems, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3985126-B1 | NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS | GENFIT (FR) | 2026-03-04 | — | — | EP | disclosed |
| EP-4355915-B1 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | GENFIT (FR) | 2026-02-04 | — | — | EP | disclosed |
| US-20260001946-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORIGINATING FROM THE ENDODERM | BT BIDCO INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2010120880-A1 | TREATMENT OF LIVER DISEASES WITH A CASPASE INHIBITOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20090093416-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-09 | — | — | US | disclosed |
| US-20090093416-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-09 | — | — | US | disclosed |
| US-20090093416-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-09 | — | — | US | disclosed |
| WO-2004106304-A2 | 3 - [2- (3-AMINO-2-OXO-2H-PYRIDIN-1-YL) - ACETYLAMINO] - 4- OXO-PENTANOIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040242494-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | TNF, NFKBIA, TRAF6 | CASP1 87/4885CASP3 63/4885CASP8 500/4885 |
| US-20260001946-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORIGINATING FROM THE ENDODERM | IL2, IL18, TSLP | CASP1 798/4885CASP3 2060/4885CASP8 242/4885 |
| US-20040242494-A1 | Caspase inhibitors and uses thereof | CASP1, CASP5, CASP3 | CASP1 1/4885CASP3 3/4885CASP8 11/4885 |
| US-20230099574-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | TNF, NFKBIA, TRAF6 | CASP1 87/4885CASP3 63/4885CASP8 500/4885 |
| US-20090093416-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP5, CASP3 | CASP1 1/4885CASP3 3/4885CASP8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.